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805-4 Biodegradable Scaffolds Incorporating Vascular 
Endothelial Growth Factor as a Novel Sustained 
Delivery Platform to Induce Angiogenesis
Qinghua Sun, Ruth Chen, David J. Mooney, Sanjay Rajagopalan, P. Michael Grossman, 
University of Michigan Hospitals and Health System, Ann Arbor, MI
Background: Therapeutic angiogenesis strategies have focused on protracted delivery
of growth factors using gene transfer approaches that are limited by potential toxicitiy and
diminished transfection rates. Polymer formulations can deliver drugs locally over time.
We hypothesized that protracted delivery of vascular endothelial growth factor (VEGF)
using a polymer [85:15 poly lactide-co-glycolide (PLG)] would result in stable neovascu-
lar networks.
Methods: C57BL/6 mice (n ~ 5/group) underwent unilateral hindlimb ischemia surgery
and were randomized to surgery only (No PLG), surgery followed by implantation of
empty scaffolds (PLG), or surgery followed by implantation of scaffolds incorporating 3µg
of VEGF165 (PLG-VEGF). At various time points, blood flow was assessed using Laser
Doppler perfusion index (LDPI, ischemic/nonischemic limb %), local tissue VEGF content
was measured by ELISA, and tissues were immunostained with CD31 and α-smooth
muscle actin (α-SMA).
Results: The PLG-VEGF formulation resulted in protracted release of VEGF (384 ± 34
pg/g at week 4). PLG-VEGF was associated with significantly better perfusioin and
enhanced CD31 and α-SMA immunostaining (Table).
Conclusion: PLG-VEGF scaffolds results in sustained VEGF delivery, improved tissue
perfusion, greater capillary density, and more mature vasculature compared to controls.
The control-released PLG polymer system is a promising delivery system for therapeutic
neovascularization applications.
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805-5 Asymmetric Dimethylarginine Impairs Angiogenesis 
and Limb Perfusion in a Murine Model of Hindlimb 
Ischemia
Johannes Jacobi, Karsten Sydow, Georges von Degenfeld, Ying Zhang, Bingyin Wang, 
Hayan Dayoub, Ken Y. Lin, Andrew J. Patterson, Masumi Kimoto, Helen M. Blau, John P. 
Cooke, Stanford University, Stanford, CA, Baxter Laboratory of Genetic Pharmacology, 
Stanford, CA
Background: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO
synthesis. ADMA is degraded by dimethylarginine dimethylaminohydrolase (DDAH).We
and others have previously shown that NO synthesis is required for normal angiogenesis,
which is impaired by ADMA.
Methods: To determine if the effects of ADMA on angiogenesis could be reversed by
overexpression of DDAH, we used DDAH 1 transgenic (TG) mice and wildytpe (WT) lit-
termates (each n=42) and employed the disk angiogenesis system (DAS) as well as a
murine model of hindlimb ischemia. Post surgery animals were treated with either PBS,
or the NOS inhibitors ADMA or Nω-nitro-L-arginine methyl ester (L-NAME; each
250µmol/kg/day) using osmotic minipumps. L-NAME is an exogenous NOS inhibitor that
is not degraded by DDAH. 
Results: Neovascularization in the DAS was significantly impaired by both NOS inhibi-
tors. However, the TG animals were resistant to the effects of ADMA and manifested
greater neovascularization. The angiogenic response(capillary density) to hindlimb
ischemia was enhanced in TG mice. In addition, TG mice were resistant to the effects of
ADMA on angiogenesis or arteriogenesis (collateral growth) which were impaired signifi-
cantly by ADMA in WT animals. These findings were confirmed by measuring hindlimb
perfusion using fluorescent microspheres. Enhanced neovascularization and limb perfu-
sion in the TG mice were associated with reduced plasma and tissue ADMA levels and
enhanced tissue NOS enzyme activity.
Conclusion: Overexpression of the enzyme DDAH reduces levels of the endogenous
NOS inhibitor ADMA, thereby increasing NO synthesis, and enhancing angiogenesis and
arteriogenesis. Therapeutic manipulation of DDAH expression or activity may represent a
novel approach to restoring tissue perfusion.
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810-1 Impact of the Angiotensin-Receptor Blocker 
Candesartan in Preventing Diabetes in Patients With 
Heart Failure
Salim Yusuf, Jan B. Ostergren, Hertzel Gerstein, Marc A. Pfeffer, Karl Swedberg, Chris B. 
Granger, John J V McMurray, and the CHARM investigators, Karolinska Hospital, 
Stockholm, Sweden, McMaster University, Hamilton, ON, Canada
Background: Type II diabetes mellitus (DM) is increasing worldwide. Therefore
approaches to prevent DM in patients who are at high risk, (such as those with hyperten-
sion and cardio-vascular disease) are needed. Previous analyses have indicated that
inhibiting the renin-angiotensin-aldosterone system (RAAS) can reduce the incidence of
DM. In the CHARM-programme we investigated whether the angiotensin receptor blocker
candesartan reduces mortality and morbidity and in addition the incidence of DM in a
broad population of patients with symptomatic chronic heart failure (CHF).
Methods: Patients with CHF were randomized to either candesartan (target dose 32 mg
o d) or placebo. Patients were enrolled in one of the three component trials;[LVEF = 40%
not receiving an ACE inhibitor due to prior intolerance (CHARM - Alternative), LVEF =
40% currently receiving an ACE inhibitor (CHARM - Added), and LVEF > 40% (CHARM -
Preserved)]. In the overall program, 5,436 of the 7,601 patients randomized did not have
a diagnosis of DM at study entry. We prospectively recorded new diagnoses of DM. 
Results: There was a significant reduction in the number of patients who were newly
diagnosed as having DM on candesartan, 163/2,715 (6.0%) compared to placebo, 202/
2,721 (7.4%); Hazard ratio, HR, of 0.78 (95% CI: 0.64-0.96); p=0.020,. Among patients
treated with ACE-inhibitors at baseline (n=3330), the HR was 0.88 (0.65-1.20); whereas
for patients not treated with an ACE-inhibitor at baseline (n=2106), HR was 0.71 (0.53-
0.93); p for interaction = 0.28.
Conclusion: In addition to reducing cardiovascular morbidity and mortality in chronic
heart failure, candesartan also reduces the risk of development of diabetes mellitus.
11:15 a.m.
810-2 Effects of Growth Hormone on Circulating Cytokine 
Dysbalance and Left Ventricular Geometry in Patients 
With Idiopathic Dilated Cardiomyopathy
Stamatis Adamopoulos, John T. Parissis, Dimitrios Karatzas, John Paraskevaidis, 
George Karavolias, Dimitrios Degiannis, Dimitrios Kremastinos, Onassis Cardiac 
Surgery Center, Athens, Greece
Background: Experimental studies have demonstrated that growth hormone (GH) can
influence left ventricular (LV) myocardial growth and remodeling in the setting of chronic
heart failure (CHF). This study investigates whether the effects of GH on LV geometry are
associated with the respective modulation of circulating proinflammatory /anti-inflamma-
tory cytokine balance in patients with CHF secondary to idiopathic dilated cardiomyopa-
thy (IDC).
Methods: Plasma proinflammatory cytokines TNF-a, IL-6, MCP-1 and anti-inflammatory
molecules IL-10 and TGF-b2 were measured (ELISA) in 12 IDC patients (NYHA class III;
LVEF: 23.6±1.7%) before and after a 3-month subcutaneous administration of GH 4IU
every other day (randomized crossover design). Peak oxygen uptake (VO2max), LV
dimensions, volumes and mass index (LVMI) were determined at the same period.
Results: A significant decrease of plasma cytokines TNF-a (7.8±1.1 vs 5.5±0.9 pg/ml,
p<0.02), IL-6 (5.7±vs 4.7±0.4 pg/ml, p<0.05) and MCP-1 (199±5 vs 184±6 pg/ml,
p<0.05), as well as a significant increase in ratio IL-10/TNF-a (1.9±0.3 vs 3.5±0.9,
p<0.05), IL-10/IL-6 (2.6±0.6 vs 3.5±0.5, p<0.05) and TGF-b2/TNF-a (3.1±0.6 vs 4.4±0.6,
p=0.05) were observed in IDC patients after GH treatment. A significant reduction in LV
end-systolic volume index (LVESVI, 128±12 vs 102±12 ml/m2, p<0.01) and LV end-dias-
tolic volume index (LVEDVI, 228±16 vs 200±14 ml/m2, p<0.05), as well as a significant
increase in posterior wall thickness (PWTH, 9.2±0.5 vs 10.3±0.6 mm, p<0.05) and
VO2max (15.3±0.7 vs 17.1±0.9 ml/kg/min, p<0.05) were also found. A good correlation
was found between GH-induced reverse LV remodeling expressed by the percentage
reduction of LVESVI and percentage increase in exercise tolerance expressed by
VO2max (r= -0.53, p=0.05). Finally, GH-induced reduction in LVESVI was significantly
correlated with respective increase of plasma IL-10/TNF-a ratio (r=0.62, p<0.01).
Conclusions: GH administration modulates beneficially circulating cytokine balance and
causes reverse LV remodeling in patients with CHF and IDC. Immunoregulatory effects of
GH may be associated with the improvement of exercise capacity and LV geometry of
IDC patients.
GROUP TIME LDPI (%) CD31/HPF α-SMA/HPF
No PLG Week 2 31 ± 3 190 ± 33 46 ± 11
Week 3 35.5±6.7 343.7±50.4 51 ± 17
Week 4 54 ± 5 434 ± 66 56 ± 18
PLG Week 2 25.0±6.6 210.5±38.4 51 ± 13
Week 3 33 ± 4 377 ± 67 59 ± 18
Week 4 40 ± 7 470 ± 81 63 ± 24
PLG-VEGF Week 2 78 ± 8*† 468 ± 45 *† 74  ± 16*†
Week 3 90 ± 7*† 615 ± 65*† 89 ± 22*†
Week 4 91 ± 4*† 789 ± 105*† 95 ± 28*†
HPF = high powered field (mean of 100 fields). *p < 0.05 for No-PLG vs. PLG-VEGF; 
†p <0.05 for PLG vs. PLG-VEGF
